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Summary 26 
This Technical Research Communication describes the efficacy of etamsylate to reduce haemolactia 27 
in dairy cows. A dairy cow with haemolactia produces milk that is reddish or pinkish due to the 28 
presence of blood. Haemolactia causes economic loss because bloody milk is rejected by the 29 
industry and the consumers. A total of 58 dairy cows with haemolactia were included in the study 30 
and randomly divided into 2 groups: a treated group (TG, n=31) and a control group (CG, n=27). 31 
Treatment (TG) consisted of three consecutive daily doses of etamsylate at 15 mg/kg (equivalent to 32 
2 mL of Hemo 125 mg/mL injectable solution/15 kg body weight), delivered intramuscularly.  Milk 33 
production (L) was recorded daily for 7 days, whether or not blood was detected in milk. The mean 34 
number of days with the presence of blood in milk in the treatment group was significantly lower 35 
(3.4 d) than in the control group (4.9 d). Treatment with etamsylate did not significantly affect milk 36 
yield. In conclusion, treatment with etamsylate reduces the number of days blood is observed in 37 
milk and it does not have any negative effect on milk production. 38 
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Haemolactia (the presence of blood in milk) is a clinical sign often observed in dairy cows, but also 42 
in other mammal species (Ayaz, 1999; George et al. 2008; Purohit et al. 2014). The main causes of 43 
haemolactia are diapedesis due to hyperaemia during the post-calving period, trauma or mastitis. 44 
Milk can be slightly tinged with blood, clots can be observed or it can be pure blood. Milk with 45 
blood is not sellable; therefore, in cases of haemolactia, farmers are concerned about economic loss, 46 
a waste of labour time and a risk of mixture with suitable milk. Etamsylate (2.5-dihydroxy-benzene-47 
sulfonate diethyl ammonium salt) is a synthetic haemostatic, anti-hemorrhagic and non-48 
thrombogenic drug indicated in cases of capillary bleeding (Garay et al. 2006). Etamsylate has been 49 
used in human and veterinary medicine for over 40 years in Europe. The first studies demonstrated 50 
an effect on primary haemostasis in several species (Laporte, 1961; Deacock & Birley, 51 
1969;Vinazzer, 1980). In cows, the haemostatic action of etamsylate could be useful in reducing 52 
bleeding in cases of haemolactia. This study was designed to evaluate the efficacy of etamsylate 53 
(Hemo 125 mg/mL injectable solution, Ecuphar, Barcelona, Spain) in reducing the presence of 54 
blood in milk in dairy cows with the aim of reducing the number of days milk has to be discarded. 55 
 56 
Materials & Methods 57 
 58 
All procedures involving animals were approved by the Ethics Committee of the University of 59 
Lleida (DAMM 0700) under EU legislation and in the spirit of good clinical practice for dairy 60 
cows. 61 
 62 
Cows with haemolactia from 9 dairy cow commercial dairy farms in Spain were included in the 63 
study. Farms milked between 135 to 1250 cows and milk yield ranged between 9100 and 11500 kg 64 
of milk per cow (3.6% Fat and 3.3% Protein) in 305 days. Cows were housed in straw-bedded, free-65 
stall barns and were fed a total mixed ration consisting of corn silage, grass silage and concentrates. 66 
All lactating cows were under regular milk quality and mastitis control carried out by specialised 67 
veterinarians. Visual examination of milk and mammary gland palpation during the milking routine 68 
was mandatory. A case of haemolactia was clinically scored as detailed in Figure 1. Milk production 69 
was recorded daily for a period of 7 days starting at the time blood was detected in milk in each of 70 
the included cows. Causes of haemolactia were established as follows: Parturition (presence of 71 
blood in milk during the first 14 days in milk (DIM); this is considered physiological but with a 72 
negative impact on the amount of milk sold), mastitis (clinical, subclinical or chronic), trauma and 73 
defects (trauma with machinery, tools, buildings on the farm; over milking; stepping on the 74 
mammary gland and udder defects), or unknown (unknown cause of presence of blood in milk). 75 
When mastitis was diagnosed, the same treatment based on antibiotics and NSAID was applied for 76 
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both groups (treatment and control negative group) in all farms. 77 
 78 
The study was designed as a randomised, blind and multicentre study. All cases fulfilling the 79 
inclusion criteria were randomised in two groups (the treatment group TG and the negative control 80 
group CG) following the randomisation list performed ad hoc for this study with the program nQuery 81 
Advisor. Cows in the TG received three consecutive daily doses of etamsylate at 15 mg/kg 82 
(equivalent to 2mL of Haemo 125 mg/ mL injectable solution/15 kg body weight), delivered 83 
intramuscularly (withdrawal period for milk: 0 days/ meat: 1 day). Cows included in the CG group 84 
received no treatment. Treatment was initiated as soon as blood in milk was detected. The primary 85 
variable for treatment efficacy evaluation was the number of days with the presence of blood in 86 
milk. As secondary variable, daily milk production was recorded for 7 days starting on the first day 87 
that blood was observed. 88 
All statistical analyses were carried out using the Statgraphics Centurion XVII (Version 17.0.16). 89 
For all analyses, the individual cow was used as the experimental unit. The significance level (P) 90 
was set at 0.05. The variables included in the statistical analyses were classified as nominal (first 91 
parturition versus multiparous cows), ordinal (parity), and quantitative non-continuous (number of 92 
days with the presence of blood in milk) or continuous (milk production). To show the homogeneity 93 
between experimental groups (TG and CG), a contingency table (Chi-square test) was used to 94 
compare the nominal variables: primiparous versus multiparous, initial blood scores and causes of 95 
haemolactia. With the aim of comparing the groups for parity, DIM and milk production at the 96 
beginning of the trial, the Mann-Whitney U test was performed. Statistical analyses were performed 97 
to compare the outcome variables between the two experimental groups (TG or CG). Thus, the 98 
number of days with the presence of blood in milk and the average milk production throughout the 99 
study (7 days) were compared between groups by means of a non-parametric Mann-Whitney U test. 100 
Finally, a survival analysis was carried out to decipher if the treatment with etamsylate shortened 101 
the duration of haemolactia versus the control group.  102 
 103 
Results 104 
A total of 58 cases were included in the study, 31 in the TG and 27 in the CG. In total, 36.2% of the 105 
cases (n=21) suffered from haemolactia during post-parturition period, 36.2% cows (n=21) had a 106 
trauma in the mammary gland and/or teats, 12.1% suffered from mastitis (n=7) and in 15.5% of the 107 
cows (n=9) the cause of haemolactia was unknown. No significant association between the parity 108 
(primiparous/multiparous) and the experimental group (TG/CG) was detected. Further, no 109 
significant differences were detected between groups for DIM, the cause of haemolactia, initial 110 
blood score and milk production between experimental groups (TG/CG) at the beginning of the 111 
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trial. These results showed the basal homogeneity between groups and allowed a comparison of the 112 
effect of treatment on the main response variables without the presence of confounding factors. 113 
Significant differences between experimental groups (TG versus CG) were observed for the days 114 
with a presence of blood in milk after treatment began including all the causes of haemolactia (TG= 115 
3.4±1.5 days and CG= 4.9±2.7 days). This result was confirmed with the survival analysis (Figure 116 
2). Treatment with etamsylate significantly shortened (P<0.05) the duration of haemolactia versus 117 
the control group. Moreover, it should be noted that the length of haemolactia was significantly 118 
higher in both groups when the cause was parturition or trauma (parturition=3.9±0.5 days and 119 
trauma= 5.0±0.5 days) compared to other causes (mastitis=3.1±0.9 days and unknown=3.6±0.7) but 120 
a significant reduction (P<0.05) was consistently observed in TG versus CG for all possible causes 121 
of haemolactia. Average milk production for the TG group (27.04±8.53 L) was higher than for the 122 
CG group (24.30±10.87 L) but the observed differences were not statistically significant (P=0.056) 123 
(Table 1). 124 
 125 
Discussion 126 
Different treatments and techniques have been studied to control or prevent haemolactia in cows: 127 
calcium solutions (Rhadostits et al., 2007), vitamin K, phytotherapy (Umadevy & Umakhanthan, 128 
2010), coagulants (Radostits et al., 2007; George et al., 2008; Zuhair, 2016), vasoconstrictors 129 
(Venkatesan et al., 2017), vitamin C, antioxidants, camphor (Raval et al., 1998), antibiotics and 130 
blood transfusion (George et al., 2008). Despite the large number of options for the treatment of 131 
haemolactia, many of these strategies lack conclusive data on cure rates, cure times and production 132 
differences between treated and untreated cows. Some of the proposed products are expensive, 133 
difficult to apply and/or cannot be applied to animals whose products are intended for human 134 
consumption. To the best of our knowledge, no previous studies have explored the use of etamsylate 135 
to treat cows diagnosed with haemolactia. According to our results, there should be registered 136 
products containing etamsylate to treat cows for haemolactia. Fortunately, there is available a 137 
registered medicinal product in Spain, Portugal, Cyprus and Malta. 138 
In conclusion, the results clearly demonstrate that treatment with etamsylate is efficacious to reduce 139 
haemolactia. Our study paves the way for additional studies on the use of etamsylate in the 140 
treatment of haemolactia in dairy cows for their productive and economic benefits. 141 
 142 
 143 
 144 
 145 
 146 
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Table 1. Effect of etamsylate treatment in cows with haemolactia (duration of the presence of blood 147 
in milk and average daily milk production for 7 days after blood detection).  148 
 149 
 TG† (n=31) CG‡ (n=27) P-value  
Presence blood in milk (d) 3.4±1.5 4.9±2.7 0.0099 (*)  
Average milk production (L) 27.±8.5 24.3±10.9 0.056 (ns)  
DIM⸹ (d) 99.8±114.8 71.7±102.7 0.1953 (ns)  
Parity 2.3±1.3 2.1±1.0 0.9461(ns)  
First parturition (%) 29.03 29.63 
0.9757 (ns) 
 
Multiparous (%) 70.97 70.37  
(*) P-value < 0.05 show significant differences. 150 
(ns) Non-significant. 151 
†TG, treated group. 152 
‡CG, control group. 153 
⸹DIM, days in milk. 154 
 155 
156 
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Figure legends: 186 
 187 
Figure 1:  188 
Milking routine and clinical scoring for blood in milk. When haemolactia was observed, the case 189 
was clinically scored as follows: no blood (0), milk slightly tinged with blood (1), milk 190 
moderately tinged with blood (2), milk severely tinged with blood (3). 191 
 192 
Figure 2: 193 
Survival analysis of the proportion (from 0 to 1) of cows with haemolactia in cows treated with 194 
etamsylate versus controls after seven days of blood detection. Dotted lines represent the 195 
95% confidence interval.  196 
 197 
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Figure 1: 221 
 222 
Score 0, no blood.  223 
Score 1, milk slightly tinged with blood.  224 
Score 2, milk moderately tinged with blood.  225 
Score 3, milk severely tinged with blood. 226 
 227 
Figure 2: 228 
 229 
 230 
